EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Genome-wide variation in cell-free DNA end-motif entropy predicts immunotherapy response in head and neck cancer

Ravi Bandaru, Hailu Fu, Haizi Zheng, Jocelyn Liang, Li Wang, Shuchi Gulati, Benjamin H Hinrichs, Mingxiang Teng, Bin Zhang, Masha Kocherginsky, De-Chen Lin, David A Hildeman und 8 weitere

Journal of Clinical Investigation · 01.07.2026 · 136 (13)

DOI: 10.1172/jci196284 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Investigation, online erschienen am 19.05.2026. Verfasst von Ravi Bandaru und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Cell-Free Nucleic Acids, Immunotherapy, Squamous Cell Carcinoma of Head and Neck. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHGRI NIH HHS, NHGRI, Northwestern University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Minimally invasive biomarkers predicting the immunotherapy response in head and neck squamous cell carcinoma (HNSCC) remain an unmet clinical need. METHODS In a prospective, multi-institutional phase II trial, we performed whole-genome sequencing of 185 longitudinal plasma cell-free DNA (cfDNA) samples from 68 patients with locally advanced, surgically resectable HNSCC who received neoadjuvant and adjuvant pembrolizumab. We developed the regional motif diversity score (rMDS), a fragmentomic metric that quantifies the entropy of cfDNA 5′-end motifs across genomic regions. RESULTS Unsupervised analysis showed that rMDS robustly distinguished responders from nonresponders, outperforming established fragmentomic metrics and copy number alterations while remaining independent of technical confounders. Longitudinal rMDS changes localized to regions enriched for immune-, lectin-, and keratinization-related genes — hallmarks of squamous cell carcinoma — reflecting tumor–peripheral immunity interplay during treatment. The most dynamic regions clustered at telomere-proximal loci, suggesting a link between telomere biology and cfDNA fragmentation. An rMDS-based machine learning classifier achieved AUC 0.89–0.99 across validation settings, with the highest accuracy after treatment, outperforming PD-L1 expression and tumor fraction in matched samples. Predicted responders showed improved disease-free survival (log-rank P = 0.035; HR 2.67, 95% CI 1.03–6.92). CONCLUSION rMDS represents a biologically meaningful and clinically actionable biomarker for the immunotherapy response in HNSCC, and merits integration into future risk assessment frameworks. TRIAL REGISTRATION ClinicalTrials.gov NCT02641093. FUNDING National Human Genome Research Institute (NHGRI), NIH grant R56HG012360; startup funds from Cincinnati Children’s Hospital Medical Center, Northwestern University, and Robert H. Lurie Comprehensive Cancer Center; Science Olympiad Alumni Research Grant, Science Olympiad USA Foundation; Merck Sharp & Dohme Corp.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Head and Neck NeoplasmsCell-Free Nucleic AcidsImmunotherapySquamous Cell Carcinoma of Head and NeckAntibodies, Monoclonal, HumanizedHumansFemaleMaleMiddle AgedProspective StudiesAgedBiomarkers, TumorEntropy

Stichwörter der Autor:innen

Cancer immunotherapyEpigeneticsGeneticsHead and neck cancerOncology

Substanzen

Cell-Free Nucleic AcidsAntibodies, Monoclonal, HumanizedBiomarkers, Tumorpembrolizumab

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
  • Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Division of Hematology/Oncology, and.
  • Department of Pathology, University of Cincinnati, Cincinnati, Ohio, USA.
  • Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida, USA.

Förderung

  • NHGRI NIH HHS
  • NHGRI
  • Northwestern University
  • Merck Sharp & Dohme Corp.
  • Cincinnati Children’s Hospital Medical Center

Zitieren

APA

Bandaru, R., Fu, H., Zheng, H., Liang, J., Wang, L., Gulati, S., Hinrichs, B. H., Teng, M., Zhang, B., Kocherginsky, M., Lin, D. C., Hildeman, D. A., Worden, F. P., Old, M., Dunlap, N. E., Kaczmar, J. M., Gillison, M. L., El-Gamal, D., Wise Draper, T., & Liu, Y. (2026). Genome-wide variation in cell-free DNA end-motif entropy predicts immunotherapy response in head and neck cancer. Journal of Clinical Investigation, 136(13). https://doi.org/10.1172/jci196284

Vancouver

Bandaru R, Fu H, Zheng H, Liang J, Wang L, Gulati S, et al. Genome-wide variation in cell-free DNA end-motif entropy predicts immunotherapy response in head and neck cancer. Journal of Clinical Investigation. 2026;136(13). doi:10.1172/jci196284

BibTeX
@article{Bandaru2026,
  author = {Bandaru, Ravi and Fu, Hailu and Zheng, Haizi and Liang, Jocelyn and Wang, Li and Gulati, Shuchi and Hinrichs, Benjamin H and Teng, Mingxiang and Zhang, Bin and Kocherginsky, Masha and Lin, De-Chen and Hildeman, David A and Worden, Francis P and Old, Matthew and Dunlap, Neal E and Kaczmar, John M and Gillison, Maura L and El-Gamal, Dalia and Wise Draper, Trisha and Liu, Yaping},
  title = {Genome-wide variation in cell-free DNA end-motif entropy predicts immunotherapy response in head and neck cancer},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {13},
  doi = {10.1172/jci196284}
}
Kostenlos starten →